Stocks
Teva Pharmaceutical Industries Financial Statements (TEVA) |
||||||||||
| Teva Pharmaceutical Industriessmart-lab.ru | % | 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.08.2023 | 09.11.2023 | 31.01.2024 | 12.02.2024 | 08.05.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3 878 | 3 850 | 4 457 | 4 457 | 3 832 | 16 596 | |||
| Operating Income, bln rub | -646.0 | 355.0 | 755.0 | 722.0 | 656.0 | 2 488 | ||||
| EBITDA, bln rub | ? | 979.0 | 1 045 | 755.0 | 1 451 | 928.0 | 4 179 | |||
| Net profit, bln rub | ? | -863.0 | 80.0 | 461.0 | 429.0 | -139.0 | 831.0 | |||
| OCF, bln rub | ? | 324.0 | 5.00 | 1 184 | 1 184 | 171.0 | 2 544 | |||
| CAPEX, bln rub | ? | 119.0 | 149.0 | 120.0 | 119.0 | 124.0 | 512.0 | |||
| FCF, bln rub | ? | 205.0 | -144.0 | 1 064 | 1 065 | 47.0 | 2 032 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 1 150 | 1 097 | 1 128 | 1 129 | 1 128 | 4 482 | ||||
| Cost of production, bln rub | 2 082 | 1 999 | 2 041 | 2 041 | 2 048 | 8 129 | ||||
| R&D, bln rub | 240.0 | 253.0 | 227.0 | 227.0 | 242.0 | 949.0 | ||||
| Interest expenses, bln rub | 268.0 | 280.0 | 0.000 | 221.0 | 250.0 | 751.0 | ||||
| Assets, bln rub | 43 095 | 42 088 | 43 479 | 43 479 | 42 773 | 42 773 | ||||
| Net Assets, bln rub | ? | 7 052 | 6 929 | 8 126 | 7 506 | 7 278 | 7 278 | |||
| Debt, bln rub | 21 016 | 20 298 | 20 153 | 20 153 | 19 938 | 19 938 | ||||
| Cash, bln rub | 2 669 | 2 249 | 3 226 | 3 226 | 2 991 | 2 991 | ||||
| Net debt, bln rub | 18 347 | 18 049 | 16 927 | 16 927 | 16 947 | 16 947 | ||||
| Ordinary share price, rub | 7.53 | 10.2 | 10.4 | 10.4 | 14.1 | 10.3 | ||||
| Number of ordinary shares, mln | 1 120 | 1 121 | 1 121 | 1 121 | 1 123 | 1 123 | ||||
| Market cap, bln rub | 8 434 | 11 434 | 11 703 | 11 703 | 15 846 | 11 567 | ||||
| EV, bln rub | ? | 26 781 | 29 483 | 28 630 | 28 630 | 32 793 | 28 514 | |||
| Book value, bln rub | -15 804 | -15 481 | -14 438 | -15 058 | -14 785 | -14 785 | ||||
| EPS, rub | ? | -0.77 | 0.07 | 0.41 | 0.38 | -0.12 | 0.74 | |||
| FCF/share, rub | 0.18 | -0.13 | 0.95 | 0.95 | 0.04 | 1.81 | ||||
| BV/share, rub | -14.1 | -13.8 | -12.9 | -13.4 | -13.2 | -13.2 | ||||
| EBITDA margin, % | ? | 25.2% | 27.1% | 16.9% | 32.6% | 24.2% | 25.2% | |||
| Net margin, % | ? | -22.3% | 2.08% | 10.3% | 9.63% | -3.63% | 5.01% | |||
| FCF yield, % | ? | 13.9% | 5.32% | 7.19% | 7.19% | 7.40% | 17.6% | |||
| ROE, % | ? | -31.7% | -31.9% | -6.49% | -7.45% | -6.77% | 11.4% | |||
| ROA, % | ? | -5.18% | -5.25% | -1.21% | -1.29% | -1.15% | 1.94% | |||
| P/E | ? | -3.78 | -5.18 | -22.2 | -20.9 | -32.1 | 13.9 | |||
| P/FCF | 7.19 | 18.8 | 11.0 | 13.9 | 13.5 | 5.69 | ||||
| P/S | ? | 0.56 | 0.75 | 0.74 | 0.74 | 0.99 | 0.70 | |||
| P/BV | ? | -0.53 | -0.74 | -0.81 | -0.78 | -1.07 | -0.78 | |||
| EV/EBITDA | ? | 6.99 | 7.59 | 7.97 | 6.68 | 7.45 | 6.82 | |||
| Debt/EBITDA | 4.79 | 4.64 | 4.71 | 3.95 | 3.85 | 4.06 | ||||
| R&D/CAPEX, % | 201.7% | 169.8% | 189.2% | 190.8% | 195.2% | 185.4% | ||||
| CAPEX/Revenue, % | 3.07% | 3.87% | 2.69% | 2.67% | 3.24% | 3.09% | ||||
| Teva Pharmaceutical Industries shareholders | ||||||||||
